4 days ago
- Health
- Wall Street Journal
No Alzheimer's Drug for Old Men?
Increasing evidence shows that anti-amyloid Alzheimer's treatments can slow disease progression and give patients years more of quality time with loved ones. So will the Trump Administration at long last drop the Biden rules that restrict access to these medicines?
Two studies presented at the Alzheimer's Association International Conference last week show that the benefits of amyloid-clearing monoclonal antibodies by Eli Lilly and Biogen-Eisai grow over time. The drugs slowed cognitive decline in clinical trials used for Food and Drug Administration approval by some 25% to 36% over 18 months. In follow-up studies, these benefits doubled at three years for Lilly's treatment and roughly quadrupled over four years for Biogen-Eisai's. That's great news for patients.
